Last reviewed · How we verify
Infliximab and immunosuppressives
Infliximab blocks tumor necrosis factor-alpha (TNF-α) to suppress inflammatory immune responses, while co-administered immunosuppressives further reduce immune activation.
Infliximab blocks tumor necrosis factor-alpha (TNF-α) to suppress inflammatory immune responses, while co-administered immunosuppressives further reduce immune activation. Used for Pediatric inflammatory bowel disease (Crohn's disease and ulcerative colitis), Severe autoimmune inflammatory conditions in children.
At a glance
| Generic name | Infliximab and immunosuppressives |
|---|---|
| Also known as | IFX, IMMs, AZA, MTX |
| Sponsor | Children's Hospital of Fudan University |
| Drug class | TNF-α inhibitor (monoclonal antibody) + immunosuppressive agents |
| Target | TNF-α receptor (via infliximab); multiple targets depending on co-administered immunosuppressive |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Infliximab is a chimeric monoclonal antibody that binds TNF-α, a key pro-inflammatory cytokine, preventing its interaction with TNF receptors and thereby reducing inflammation. When combined with immunosuppressive agents (such as methotrexate or azathioprine), this regimen provides synergistic immune suppression, reducing both TNF-mediated and broader T-cell-driven inflammatory pathways. This combination approach is commonly used in pediatric inflammatory bowel disease and other severe autoimmune conditions.
Approved indications
- Pediatric inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Severe autoimmune inflammatory conditions in children
Common side effects
- Infections (bacterial, viral, fungal)
- Infusion reactions
- Hepatotoxicity
- Bone marrow suppression
- Opportunistic infections (tuberculosis, PCP)
Key clinical trials
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation (NA)
- Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib (PHASE4)
- InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease (PHASE3)
- Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: